Amneal Reports Second Quarter 2026 Financial Results
Amneal Pharmaceuticals announced robust financial results for Q2 2026, with net revenue of $796 million, a 10% increase year-over-year, and net income increasing by 157% to $58 million. The company raised its full-year 2026 guidance, highlighted strong performances in specialty and affordable medicines segments, and completed a debt repricing to re…